Incresync (Pioglitazone, Alogliptin)

• Incresync combines a thiazolidinedione and a DPP‑4 inhibitor to manage hyperglycemia in type 2 diabetes.
• Type 2 diabetes mellitus: reduces fasting and post‑prandial glucose levels to improve overall glycemic control.
• Adjunct therapy for inadequate monotherapy: adds insulin‑sensitising and incretin‑enhancing effects when other agents alone are insufficient.
• Combination therapy for patients requiring dual mechanisms: provides both PPARγ activation and DPP‑4 inhibition in a single oral regimen.

• Pioglitazone activates peroxisome proliferator‑activated receptor‑γ (PPARγ), enhancing transcription of genes involved in glucose uptake and lipid metabolism, which improves insulin sensitivity. Alogliptin inhibits dipeptidyl peptidase‑4 (DPP‑4), preventing degradation of endogenous incretin hormones (GLP‑1 and GIP), thereby increasing glucose‑dependent insulin secretion and suppressing glucagon release. The combined actions result in better glycaemic control in type 2 diabetes.

Incresync is associated with several adverse reactions that vary in frequency and severity.

Common Side Effects

• Edema: peripheral swelling, especially in the lower limbs.
• Weight gain: modest increase in body weight.
• Upper respiratory tract infection: mild cold‑like symptoms.
• Headache: transient cranial discomfort.
• Dizziness: occasional light‑headedness.
• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.

Serious or Rare Side Effects

• Congestive heart failure: signs of fluid overload and reduced cardiac function.
• Hepatotoxicity: elevated liver enzymes or liver injury.
• Severe hypoglycaemia: particularly when combined with insulin or sulfonylureas.
• Pancreatitis: acute abdominal pain with elevated pancreatic enzymes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Bone fracture: increased risk of femoral fractures in some patients.

• Before initiating Incresync, clinicians should consider several safety measures.
• Monitor liver function: obtain baseline hepatic enzymes and repeat periodically.
• Assess for heart failure: avoid use in patients with active or uncontrolled congestive heart failure.
• Evaluate renal function: dose adjustment may be required in severe renal impairment.
• Avoid in active bladder cancer: pioglitazone is contraindicated in this condition.
• Use caution in the elderly: increased susceptibility to fluid retention and hypoglycaemia.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture.

Incresync may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid)

• Concomitant insulin or sulfonylureas: heightened risk of hypoglycaemia.
• Strong CYP2C8 inhibitors (e.g., gemfibrozil): increased pioglitazone exposure.
• Strong CYP3A4 inducers (e.g., rifampicin): reduced alogliptin plasma levels.
• Loop diuretics: may exacerbate fluid retention.
• Anticoagulants (warfarin): possible alteration of INR.

Moderate Interactions (Monitor Closely)

• NSAIDs: may increase risk of renal impairment and fluid retention.
• ACE inhibitors or ARBs: monitor for additive effects on renal function and potassium.
• Oral contraceptives: potential reduction in alogliptin efficacy.
• Statins: monitor for rare myopathy when combined with pioglitazone.
• Thyroid hormones: assess glycaemic control as thyroid status can affect glucose metabolism.